RxDoctor Payments Data

Nicholas Lewis, MD

Internal Medicine · Eagle, IDNPI 1134372386

Payments from drug & device makers

$289in general payments, 2019–2025

Across 17 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$76
  • Boehringer Ingelheim$76
  • Johnson & Johnson$36
  • Novo Nordisk$27
  • Teva Pharmaceuticals USA, Inc.$26
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$289 in reported general payments places this provider in the 75th percentile of 289 internal medicine providers in Idaho.

See all internal medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$26,896
Medicare patients
127
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$105,833
OzempicSemaglutide65$88,959
JardianceEmpagliflozin57$80,347
FarxigaDapagliflozin Propanediol34$45,937
JanuviaSitagliptin Phosphate44$42,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,677
XareltoRivaroxaban20$29,736
MounjaroTirzepatide26$28,177
Repatha SureclickEvolocumab21$16,517
MyrbetriqMirabegron11$13,628
Tresiba Flextouch U-100Insulin Degludec20$10,934
Atorvastatin Calcium742$7,924
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,314
Arnuity ElliptaFluticasone Furoate15$5,922
SymbicortBudesonide/Formoterol Fumarate12$3,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$105,83380 claims
Novo NordiskOzempic$27$88,95965 claims
Boehringer IngelheimJardiance$76$80,34757 claims
AstraZenecaFarxiga, Symbicort$76$49,78246 claims
Johnson & JohnsonXarelto$36$29,73620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 289 internal medicine providers in Idaho.

Other internal medicine in Eagle

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →